Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by Anika Therapeutics, Inc. on July 9, 2024. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metric.
Material Changes
As this document reports on a specific event (the Annual Meeting) rather than a comparative financial period, there are no material changes in financial metrics to report. The primary material event is the successful election of the board of directors and ratification of the independent auditor.
Outlook, Risks, and Voting Results
The filing provides final voting results for three proposals submitted to stockholders. A total of 12,387,064 shares were present, representing 83.37% of the voting power.
- Proposal 1 (Election of Directors): All three Class I director nominees were elected to serve until the 2027 Annual Meeting.
- Sheryl L. Conley: 10,713,825 For; 415,055 Against; 27,858 Abstain.
- William R. Jellison: 11,092,818 For; 13,085 Against; 50,835 Abstain.
- Stephen O. Richard: 10,205,467 For; 924,213 Against; 27,058 Abstain.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes: 12,337,376 For; 43,654 Against; 6,034 Abstain.
- Proposal 3 (Say-on-Pay): Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers.
- Votes: 11,020,273 For; 129,717 Against; 6,748 Abstain.
The filing does not contain specific management commentary on future outlook, risks, contingencies, or unusual items beyond the standard disclosure of the meeting results.
Investor Verification Checklist
- Verify the tenure of the newly elected directors (Sheryl L. Conley, William R. Jellison, Stephen O. Richard) through the 2027 Annual Meeting.
- Confirm the appointment of Deloitte & Touche LLP as the auditor for the fiscal year ending December 31, 2024.
- Review the Proxy Statement filed on June 11, 2024, for detailed compensation data referenced in Proposal 3.
- Note that this 8-K contains no financial results; refer to the most recent 10-Q or 10-K for financial performance.